PMID- 30306221
OWN - NLM
STAT- MEDLINE
DCOM- 20190903
LR  - 20210109
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Print)
IS  - 0937-941X (Linking)
VI  - 30
IP  - 2
DP  - 2019 Feb
TI  - Hepatocyte growth factor is a potential biomarker for osteoproliferation and 
      osteoporosis in ankylosing spondylitis.
PG  - 441-449
LID - 10.1007/s00198-018-4721-4 [doi]
AB  - We explored relations between serum hepatocyte growth factor (HGF), disease 
      activity, osteoproliferation, and bone mineral density (BMD) in ankylosing 
      spondylitis (AS), in comparison with healthy controls. HGF was increased 
      especially in male AS patients and smokers and associated with both lower BMD and 
      more chronic radiographic changes in the spine. INTRODUCTION: Ankylosing 
      spondylitis (AS) is characterized by both osteoproliferation and increased bone 
      loss. Biomarkers are requested to predict the processes. The aims of this study 
      were to compare serum levels of hepatocyte growth factor (HGF), matrix 
      metalloproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF) in AS 
      patients with healthy controls (HC) and to explore the associations with disease 
      activity, osteoproliferation, and bone mineral density (BMD). METHODS: Serum from 
      AS patients (modified NY-criteria) and HC was analyzed for HGF, MMP-3, and VEGF 
      with ELISA. Disease activity parameters were collected. Osteoproliferation was 
      assessed with modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and BMD 
      was measured in femoral neck. RESULTS: Totally, 204 AS patients and 80 sex and 
      age matched HC were included. Serum HGF was higher in the AS patients compared 
      with the HC, whereas serum MMP-3 and VEGF were not. Serum HGF was also higher in 
      smokers and in the male AS patients positively correlated with age, BASMI, and 
      mSASSS, and negatively correlated with BMD. The biomarkers were all positively 
      associated with ESR, CRP, and WBC. In multiple linear regression analysis serum 
      HGF remained associated with higher mSASSS and lower BMD, after adjusting for 
      age, sex, CRP, smoking, and body mass index. CONCLUSIONS: Serum HGF was increased 
      in male AS patients and associated with higher mSASSS and lower BMD. In addition, 
      serum HGF was positively associated with risk factors for osteoproliferation such 
      as age, CRP and smoking. HGF could be a potential biomarker of importance for the 
      bone metabolism in AS. TRIAL REGISTRATION: NCT00858819.
FAU - Torres, L
AU  - Torres L
AD  - Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at the 
      University of Gothenburg, Guldhedsgatan 10A, S-413 46, Gothenburg, Sweden.
FAU - Klingberg, E
AU  - Klingberg E
AUID- ORCID: 0000-0001-6858-6413
AD  - Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at the 
      University of Gothenburg, Guldhedsgatan 10A, S-413 46, Gothenburg, Sweden. 
      Eva.Klingberg@vgregion.se.
FAU - Nurkkala, M
AU  - Nurkkala M
AD  - Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at the 
      University of Gothenburg, Guldhedsgatan 10A, S-413 46, Gothenburg, Sweden.
FAU - Carlsten, H
AU  - Carlsten H
AD  - Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at the 
      University of Gothenburg, Guldhedsgatan 10A, S-413 46, Gothenburg, Sweden.
FAU - Forsblad-d'Elia, H
AU  - Forsblad-d'Elia H
AD  - Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at the 
      University of Gothenburg, Guldhedsgatan 10A, S-413 46, Gothenburg, Sweden.
AD  - Department of Public Health and Clinical Medicine, Rheumatology, Umea University, 
      Umea, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT00858819
PT  - Journal Article
DEP - 20181010
PL  - England
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation 
      between the European Foundation for Osteoporosis and the National Osteoporosis 
      Foundation of the USA
JID - 9100105
RN  - 0 (Biomarkers)
RN  - 0 (HGF protein, human)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Absorptiometry, Photon/methods
MH  - Adult
MH  - Aging/blood
MH  - Biomarkers/blood
MH  - Bone Density/physiology
MH  - Case-Control Studies
MH  - Female
MH  - Femur Neck/physiopathology
MH  - Hepatocyte Growth Factor/*blood
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Osteogenesis/*physiology
MH  - Osteoporosis/diagnosis/*etiology/physiopathology
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/blood/*complications/pathology/physiopathology
MH  - Vascular Endothelial Growth Factor A/blood
PMC - PMC6449322
OTO - NOTNLM
OT  - Ankylosing spondylitis
OT  - Hepatocyte growth factor (HGF)
OT  - Matrix metalloproteinase-3 (MMP-3)
OT  - Osteoporosis
OT  - Osteoproliferation
OT  - Vascular endothelial growth factor (VEGF)
COIS- ETHICAL APPROVAL: All procedures performed involving human participants were in 
      accordance with the ethical standards of the institutional and/or national 
      research committee and with the 1964 Helsinki declaration and its later 
      amendments or comparable ethical standards. INFORMED CONSENT: Informed consent 
      was obtained from all individual participants included in the study. CONFLICTS OF 
      INTEREST: None.
EDAT- 2018/10/12 06:00
MHDA- 2019/09/04 06:00
PMCR- 2018/10/10
CRDT- 2018/10/12 06:00
PHST- 2018/05/05 00:00 [received]
PHST- 2018/09/26 00:00 [accepted]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2019/09/04 06:00 [medline]
PHST- 2018/10/12 06:00 [entrez]
PHST- 2018/10/10 00:00 [pmc-release]
AID - 10.1007/s00198-018-4721-4 [pii]
AID - 4721 [pii]
AID - 10.1007/s00198-018-4721-4 [doi]
PST - ppublish
SO  - Osteoporos Int. 2019 Feb;30(2):441-449. doi: 10.1007/s00198-018-4721-4. Epub 2018 
      Oct 10.